year left
short interest float
technolog inc clinic stage biotechnolog compani
develop treatment variou oncolog indic compani lead asset
novel combin therapi base target exploit uniqu metabol
cancer cell date approxim patient treat compani
shown complet partial respons differ cancer type current
phase ii develop refractori pancreat cancer biomarker-recurr non-
metastat prostat cancer data readout studi expect year end
earli
point discuss
combin therapi design target metabol capabl
cancer tyme lead asset combin therapi compris proprietari
mixtur dysfunct tyrosin deriv rapamycin methoxsalen phenytoin
unlik oncolog drug target specif mutat compound
design target uniqu metabol capabl cancer cell allow
potenti use therapi multipl solid tumor type preliminari data use
show anti-tumor respons sever tumor type includ
breast appendix pancrea lung thyroid base result
initi develop refractori pancreat cancer biomarker-recurr non-
favor safeti profil posit cancer patient cancer
therapi truli tumor specif lead patient frequent experienc treatment
relat advers event rang grade mild grade life-threaten
death case addit toxic cancer therapi prohibit
use elderli late stage patient may less abl toler treatment
also patient priorit qualiti life defer toxic therapi even effect
one uniqu featur toler safeti profil
seriou drug-rel grade advers event observ patient
treat clinic trial thu far commonli report ae
hyperpigment like result methoxsalen act increas melanin
product patient second commonli report ae fatigu
gener transient like side effect increas tyrosin
administ patient potenti use wide rang
patient approv could competit advantag seek treatment
option rel benign safeti profil
result clinic preclin collabor academ partner
ye final phase ib/ii data non-metastat recurr
ye interim analysi phase ii pancreat cancer trial
analyst certif disclosur pleas see page
phase ii pancreat cancer data expect ye earli pancreat cancer one
deadliest form cancer surviv rate approxim patient patient
metastat diseas previous conduct first-in-human fih compassion use program
perform retrospect chart review patient advanc metastat recurr pancreat
cancer compassion use program gener equival fih studi howev combin therapi
treatment allow result show forti percent evalu patient demonstr
surviv month achiev complet monotherapi partial respons
monotherapi combo eighti percent patient show improv ecog perform statu
first treatment cycl percent demonstr improv greater one point
six-week period median month initi therapi patient improv
maintain subject-report health qualiti life outcom interim analysi studi expect
ye earli
potenti prostat cancer base preliminari result evalu phase ib/ii
trial non-metastat prostat cancer patient fail declin androgen depriv therapi
interim result show dose limit toxic dlt drug relat seriou advers event
report patient show improv circul tumor cell ctc count show radiograph
progress free surviv rpf patient sought subsequ toxic therapi blood stream
often earli indic metastasi patient prostat cancer report treat patient
least reduct addit patient demonstr least one ctc measur report
undetect treatment occur median period week
second-lin set would directli compet treatment option array
signific treatment-rel includ sexual dysfunct chang bodi composit cognit defect
metabol effect could give distinct advantag continu show favor safeti efficaci
profil clinic trial
june report financi result fiscal year financi period
shown figur year end compani cash cash equival million
figur financi figur fiscal year
tabl content
combin therapi target cancer metabol
earli clinic data result first-in-human fih studi compassion use program
use multipl tumor type
assess safeti efficaci tyme first-in-human studi
safeti profil
clinic data discuss treatment pancreat cancer
preliminari result pancreat cancer patient fih compassion use program
phase ii trial metastat pancreat cancer
competit landscap pancreat cancer
prostat cancer
clinic data discuss treatment prostat cancer
phase ib/ii studi prostat cancer
competit landscap local prostat cancer
risk invest
technolog inc clinical-stag biotechnolog compani develop cancer therapeut variou
oncolog indic compani lead asset combin therapi compris proprietari mixtur
dysfunct tyrosin deriv rapamycin methoxsalen phenytoin unlik oncolog drug target
specif mutat compound design target uniqu metabol capabl cancer cell
allow potenti use therapi multipl solid tumor preliminari data use across tumor
type show monotherapi anti-tumor respons sever tumor type includ breast
appendix pancrea lung thyroid base result assess phase ii trial
treatment metastat pancreat cancer interim analysi expect year end earli first
quarter also evalu phase ii clinic trial treatment biomarker-recurr
non-metastat prostat cancer final result expect year end earli first quarter
compani therapeut pipelin shown figur
combin therapi target cancer metabol
sinc earli appreci cancer cell alter metabol glucos compar
normal tissu cancer cell consum tremend amount glucos primarili metabol lactat even
presenc cancer cell also increas uptak lipid amino acid contribut cell
growth surviv prefer ferment sourc energi rather mitochondri oxid
phosphoryl cancer cell known warburg effect aerob glycolysi effort develop therapi
exploit phenomenon includ target glucos uptak lactat product unfortun limit
success clinic due toxic
unlik previou therapi combin monotherapi design affect aerob glycolysi
util sever synergist mechan action includ inhibit protein translat promot oxid
stress expos cancer bodi immun system approach unlik target therapi
attempt regul specif mutat within certain cancer type may allow activ multipl
solid tumor type although mechan action fulli elucid earli clinic data suggest
may effect therapeut option patient relaps follow tradit cancer therapi
patient seek less toxic treatment option compar chemotherapi toxic profil mild
compris three repurpos fda approv compound dysfunct amino acid
proprietari combin low sub-therapeut dose rapamycin mg methoxsalen mg
phenytoin mg racem mixtur l- d-tyrosin enantiom clinic trial administ
twice day patient receiv rapamycin methoxsalen phenytoin day tyrosin mixtur twice
day brief synops compound explan provid follow mechan
rapamycin sirolimu inhibitor mammalian target rapamycin mtor drug divers
function includ limit halt progress cell phase cell
cycl act potent immunosuppress prevent reject organ
rapamycin util push bodi pseudo-ketot state
methoxsalen natur occur furocoumarin compound approv treat skin diseas vitiligo
psoriasi commonli use combin ultraviolet light due photoactiv
methoxsalen propos increas ro bodi order serv catalyst oxid
reaction drive cell death cancer cell
phenytoin dilantin antiepilept drug use treat seizur use lower dose
drug induc appear stabil threshold hyperexcit neuron
promot sodium efflux phenytoin propos drive increas ro
cell increas reactiv lipid speci tumor microenviron drive cell death cancer cell
racem l-/d-tyrosin isom tyrosin non-essenti amino acid use build block
protein synthesi l-tyrosin use cell structur d-tyrosin imped
properli util machineri mammal cell protein translat propos
doherti cleveland target lactat metabol cancer therapeut clin invest
hamanaka chandel target glucos metabol cancer therapi
hay reprogram glucos metabol cancer exploit cancer therapi cancer
l-tyrosin act transport help d-tyrosin enter cancer cell subsequ interfer
inhibit protein synthesi cell
mechan action
design take advantag cellular weak result warburg effect cancer
drug potenti caus destabil tumor sever mechan promot cell death
emphas studi necessari fulli elucid mechan action compani
partner academ institut provid experiment evid mechan action
addit detail expect figur depict propos therapeut role compon sm-
figur hypothes mechan action
mechan action separ two main categori includ disrupt protein translat
increas level reactiv oxygen speci ro tumor describ detail
disrupt protein translat insuffici carbohydr level extern food
sourc util energi bodi transit metabol state known ketosi fat
instead use transit ketosi stimul upregul l-type amino acid
transport cell function increas movement amino acid extracellular
environ
paoli et al beyond weight loss review therapeut use very-low-carbohydr ketogen diet european
journal clinic nutrit
fan et al impact system amino acid transport prolifer human ovarian cancer cell
possibl target combin therapi anti-prolif aminopeptidas inhibitor biochem pharmacolog
exploit process use low-dos rapamycin leucin aminopeptidas inhibitor push
bodi pseudo-ketot state result decreas mtor signal lead increas
uptak amino acid cancer cell via cancer cell unabl synthes suffici tyrosin
phenylalanin need instead cell must acquir tyrosin cellular environ
make amino acid uniqu target featur sinc incap transport d-tyrosin across
cell membran racem d- l-tyrosin isom bound van der waal forc
compani specif bind procedur allow l-tyrosin act anchor move d-tyrosin across
lipid bilay cell d-tyrosin interfer inhibit cellular protein synthesi although
definit shown inhibit protein synthesi may reduc express mucin glycoprotein
upregul approxim increas mucin level extracellular surfac physic
shield cancer recognit immun system also caus upregul enzym
superoxid dismutas reduc elev ro cell caus warburg
drive increas reactiv oxygen speci ro maintain appropri balanc ro
essenti cancer cell surviv depict figur excess ro damag cell membran
nucleic acid deleteri effect wherea insuffici ro disturb signal process
benefici cell prolifer mention warburg effect caus increas
level ro cancer cell left uncontrol would drive cell death via balanc
level ro cancer cell upregul enzym superoxid dismutas catalas glutathion
peroxidas mitig unintend increas ro caus aerob glycolysi potenti
manipul mucin level may thu act bridg disrupt protein translat
increas ro level thu offset ro balanc caus increas reactiv potenti cancer
figur effect increas ro level cancer cell
modifi pourahmad salimi seydi
singh bandyopadhyay target molecul cancer therapi cancer biolog therapi
putten transmembran mucin signal receptor intersect inflamm cancer journal
horm schroeder metastat cancer express function therapeut target cell adh
liberti locasal warburg effect benefit cancer cell trend biochem
addit cancer cell show strong prefer lipid cholesterol support increas metabol
demand result exploit uniqu characterist cancer cell phenytoin methoxsalen
use drive increas ro cell increas reactiv lipid speci tumor microenviron
increas ro bodi order serv catalyst oxid reaction mechan propos
increas ro balanc beyond surviv threshold cancer cell lead cell death via apoptosi
depict figur
rational compon support propos mechan action
emphas preclin studi perform confirm hypothes scienc continu
evolv better understand mechan achiev on-going research current
perform academ institut contract research organ collabor
first set preclin data anticip releas septemb
date preclin studi test compon anim model determin
safeti explor propos mechan action combin therapi howev singl
preclin studi recent perform test safeti tyrosin isom spragu dawley rat beagl
dog present european societi medic oncolog esmo confer dose
escal repeat dose toxicolog studi perform assess sever paramet includ
mortal clinic observ chang bodi weight food consumpt electrocardiographi ophthalmolog
blood sampl collect day eight time point rel treatment order determin
toxicokinet profil
unschedul death clinic sign chang bodi weight food consumpt effect ecg ocular
find chang hematolog coagul clinic chemistri urinalysi paramet macroscop
microscop find could attribut administr tyrosin isom dose
mg/kg/day chang bodi weight observ could attribut administr tyrosin
isom mg/kg/day howev consecut day use mg/kg/day male rat result reduct
mean bodi weight gain correl decreas food consumpt dose-rel increas mean
bodi weight gain femal dose group dog observ overal conclud
tyrosin isom safe well toler anim model state previous addit preclin data
anticip releas septemb shed light mechan action efficaci
djefaflia vasseur guillaumond lipid metabol reprogram cancer cell oncogenesi
earli clinic data result first-in-human fih studi compassion use
program use multipl tumor type
assess safeti efficaci tyme first-in-human studi
trial design tyme first-in-human fih trial irb approv studi metastat cancer initi
origin design safeti studi elig patient progress metastat
diseas compris follow cancer type breast lung pancreat
thyroid cancer compon given oral subcutan day week
week constitut one treatment cycl protocol extend follow confirm accept
safeti profil earli posit respons therapi
result septemb analysi show object respons rate orr base
recist criteria includ patient breast appendix experienc complet respons cr
patient breast pancreat lung thyroid experienc partial respons pr figur show durat
treatment overal surviv os patient studi median os month
figur data analysi tyme first-in-human studi
addit patient prior data avail therapi use enrol tyme fih studi
patient median month prior therapi compar median month
time longer end studi patient progress free patient
signific reduct increas tumor size thu classifi stabl
diseas patient enter studi activ progress metastat diseas find suggest sm-
may interf tumor progress support positron emiss topographi pet imag
metastat breast cancer patient studi show lesion becam metabol inact one cycl
treatment even though lesion size exhibit signific reduct tumor volum time
howev analysi patient month compar baselin show patient complet respons
cr determin recist criteria thu tradit recist respons criteria may fulli highlight
therapeut benefit patient receiv treatment result pet imag incorpor
compani two on-going clinic trial monitor metabol statu cancer
compassion use program patient qualifi inclus fih studi
offer enrol compassion use program provid treatment fih
trial patient could continu receiv therapeut intervent concurr time compani
report orr evalu patient program divid cancer
type respons figur clinic benefit respons cbr patient program
figur result patient compassion use program
patient monotherapi
figur summari clinic result
figur provid summari result patient compani fih monotherapi compassion use
program allow therapeut intervent use concurr well report pool result
two studi current efficaci evalu phase ii clinic trial treatment
recurr non-metastat prostat cancer phase ii trial treatment metastat pancreat cancer
discuss detail therapeut indic interim result pancreat cancer trial
final result prostat cancer trial expect announc around ye earli
safeti profil
one uniqu featur toler safeti profil seriou drug-rel
grade advers event observ patient treat thu far clinic trial
commonli report ae hyperpigment like result methoxsalen act increas
melanin product patient second commonli report ae fatigu gener
transient like side effect increas tyrosin administ patient figur display
advers event report fih studi
figur treatment-rel advers event fih studi
safeti profil on-going phase ib/ii studi assess safeti efficaci patient
biomarker-recurr non-metastat prostat cancer also favor note report differ
fih studi includ vitiligo hot flash intestin bloat flatul patient grade
higher drug-rel advers event report patient assess studi thu far addit
safeti data expect report around ye phase ii trial prostat
pancrea organ locat behind stomach secret hormon includ insulin help
bodi process sugar consum food well produc digest enzym help bodi digest food
pancreat cancer expect diagnos roughli new patient us year third
common caus cancer-rel death us lead death per year diseas limit number
effect treatment option surviv rate approxim patient
patient metastat diseas poor prognosi result sever factor includ new patient gener
diagnos late stage due asymptomat natur earli pancreat cancer also lack reliabl screen
test treatment option includ surgeri radiat therapi patient present unresect diseas
patient advanc diseas hand chemotherapi approv fda
sever advers event patient decreas patient qualiti life lack effect therapi
minim side effect potenti meet unmet need clinic evalu necessari determin
efficaci pancreat cancer earli result patient diseas fih
compassion use program encourag
caus pathogenesi pancrea organ locat behind stomach depict figur
endocrin function secret hormon insulin glucagon help bodi maintain glucos level
also exocrin function produc enzym aid digest major malign neoplasm
develop pancrea classifi adenocarcinoma neuroendocrin tumor acinar carcinoma also
aris pancrea molecular pathogenesi pancreat cancer well character almost
tumor carri initi mutat kra oncogen mutat also
predomin addit c-kit recent propos enhanc invas pancreat
despit strong understand underli genet correspond advanc
target therapeut associ gain patient outcom
zhang et al stem cell factor/c-kit signal enhanc invas pancreat cancer cell via normox
figur locat pancrea digest system
symptom diagnosi patient pancreat cancer rare earli symptom diseas
cancer progress often present sever abdomin pain jaundic loss appetit weight loss diarrhea
nausea diagnosi pancreat cancer gener made evalu symptom may includ imag
test ct scan mri ultrasound blood test liver function test identif tumor
marker biopsi
treatment option fda approv therapi pancreat cancer shown figur mention
previous treatment typic includ surgeri radiat chemotherapi patient
elig surgeri due fact time diagnosi tumor spread beyond pancrea
metastat diseas substanti difficult treat local tumor gemcitabin use
nearli two decad first-lin treatment regimen advanc metastat pancreat cancer
figur approv pancreat cancer
celgen celg abraxan albumin bound paclitaxel approv combin
gemcitabin first-lin pancreat cancer base result phase studi show median overal surviv
month combin gemcitabin compar month gemcitabin detail primari
first line therapi pancreat cancer shown figur along folfirinox oxaliplatin
irinotecan fluorouracil leucovorin commonli use therapi first-lin treatment result
patient random studi show treatment folfirinox result median os
month respect compar median os month month respect patient
figur primari first line therapi pancreat cancer
notabl grade
thromboembol elev
follow progress gemcitabin abraxan treatment consist number chemotherapi combin
regimen use label folfox folin acid fluorouracil oxaliplatin folfiri
leucovorin irinotecan capox oxaliplatin capecitabin gemcitabin docetaxel
capecitabin clinic trial result use treatment dismal surviv singl
digit month exampl second-lin folfox metastat pancreat cancer patient result singl
respons patient achiev stabl median os patient
von hoff et al increas surviv pancreat cancer nab-paclitaxel plu gemcitabin new england journal
medicin
conroy et al folfirinox versu gemcitabin metastat pancreat cancer new england journal medicin
conroy et al folfirinox versu gemcitabin metastat pancreat cancer new england journal medicin
von hoff et al increas surviv pancreat cancer nab-paclitaxel plu gemcitabin new engalnd journal
zaanan et al folfox second-lin chemotherapi patient pretreat metastat pancreat cancer
firgem studi bmc cancer
ipsen epa ipn pa onivyd nanoliposom irinotecan approv combin fluorouracil
leucovorin patient metastat adenocarcinoma pancrea progress gemcitabine-bas
therapi treatment approv base phase napoli-i trial show median os
orr month month respect compar median os orr month
month thu consider need improv therapi pancreat
address us market roughli peopl expect diagnos pancreat cancer us alon
patient receiv form treatment within year
pancreat cancer patient elig surgeri requir therapeut treatment intervent
first-lin combin gemcitabin patient fail first-lin treatment
healthi enough second-lin therapi due advers event associ scenario
conserv estim total address market approxim patient could elig
second-lin set year howev consid favor toxic profil patient
fail first-lin treatment may elig second-lin treatment mean estim annual
address us market approxim patient final calcul present figur
figur us market opportun pancreat cancer
project number pancreat cancer
patient elig treatment
diagnos
wang-gillam et al nanoliposom irinotecan fluorouracil folin acid metastat pancreat cancer
walker ej ko ah beyond first-lin chemotherapi advanc pancreat cancer expand array
aroldi et al pancreat cancer new hope first line treatment world gastrointest oncol
onyvid fda approv treatment option gemcitabine-refractori pancreat cancer patient ipsen
compani market drug project peak sale approxim million year second-lin
approv tyme could directli compet market superior safeti profil could
differenti factor uptak howev stress data on-going phase ii pancreat cancer
studi essenti determin drug efficaci larger patient popul
clinic data discuss treatment pancreat cancer
preliminari result pancreat cancer patient fih compassion use program
trial design retrospect chart review perform subject advanc metastat recurr
pancreat cancer treat fih compassion use program three
subject identifi fih studi addit case pancreat cancer identifi
subject compassion use program treatment compassion use program gener
equival fih studi howev combin therapi allow physician supervis
patient identifi evalu data analysi evalu overal surviv os overal
pain score although treatment regimen specif vari provid therapi five day week
administ clinician oral subcutan inject patient receiv monotherapi
result shown figur forti percent evalu patient demonstr surviv
month achiev complet partial respons eighti percent patient
show improv ecog perform statu first treatment cycl percent
demonstr improv greater one point six-week period patient improv
maintain european organ research treatment cancer eortc qualiti life questionnair
subject-report health qualiti life outcom initi therapi median month
one subject stabl diseas overal surviv month treatment one stabl
diseas subject overal surviv month
hoffman stega zawisni gostout del prior loushin taylor br therapi patient
figur safeti efficaci result pancreat cancer patient
treatment
receiv addit therapi immunotherapi chemotherapi treatment
phase ii trial metastat pancreat cancer
trial design open-label phase ii studi evalu plan patient refractori
metastat pancreat cancer fail line prior therapi studi divid two stage
shown figur first stage expect enrol patient receiv either high dose mg low dose
mg tyrosin isom conjunct unchang rapamycin methoxsalen phenytoin
follow interim analysi second portion studi expect enrol roughli addit patient
depend outcom first stage trial singl defin dose tyrosin isom
administ patient along compound endpoint studi includ
progress free surviv overal surviv os object respons rate orr trial initi
march interim analysi expect releas year end earli first quarter
figur overview phase ii trial metastat pancreat cancer
competit landscap pancreat cancer
pancreat cancer difficult diseas treat caus third deadliest malign us
approxim death predict difficulti result signific barrier drug develop
includ aggress diseas morpholog featur diseas prevent optim drug deliveri
late-lin patient popul order gain market share second-lin pancreat cancer treatment
need show signific improv overal surviv toler compar folfox mpf
month mo month combin onyvide/fluorouracil/leucovorin mpf month mo
mention previous onyvid fda approv treatment option gemcitabine-refractori pancreat
cancer patient project annual revenu approxim million year treatment second-
line approv tyme would directli compet market may well result
superior safeti profil howev stress data on-going phase ii pancreat cancer studi
essenti determin drug efficaci larger metastat pancreat cancer patient popul
prostat cancer
prostat gland male reproduct system locat pelvi situat urinari bladder
primari function produc semin fluid nourish transport sperm cell within prostat
begin prolifer uncontrol prostat cancer aris prostat cancer third preval cancer
us project approxim men us diagnos due locat
relat tissu pelvi treatment prostat cancer undesir side effect includ sexual
dysfunct urinari incontin lead mani patient doctor choos activ surveil
diseas progress approv first- second-lin set may provid patient non-
hormon altern treatment option improv side effect profil compar avail treatment
could util chronic mainten therapi current assess efficaci phase ii
trial patient non-metastat biomarker-recurr prostat cancer
caus pathogenesi exact caus prostat cancer unknown diseas aris cell within
organ begin prolifer uncontrol mass cell put pressur onto urethra shown figur
neg affect urin potenc cancer develop variou histolog form includ
adenocarcinoma prostat cancer sarcoma small cell carcinoma neuroendocrin tumor variou
risk factor associ diseas high blood pressur obes smoke well genet
alter link gene dna repair pathway includ
figur depict prostat cancer caus symptom
symptom detect men earli stage prostat cancer usual asymptomat cancer progress
patient experi weak interrupt urin flow frequent urin blood urin pain burn
sensat urin men advanc diseas often develop bone metastasi frequent experi pain
hip spine rib well area
detect prostat cancer util combin test includ screen physic examin imag
prostat specif antigen screen minim invas blood test measur serum level
compon semin fluid produc almost exclus prostat shown elev
men prostat cancer although alway accur screen current first line defens
screen men prostat cancer level elev physician may perform physic digit rectal
examin determin size shape textur prostat event high rise
level detect suggest presenc prostat cancer imag via transrect ultrasound tru
magnet reson imag mri perform procedur often take less minut produc
detail pictur structur within man prostat gland imag allow physician evalu size
prostat gland extent prostat cancer whether cancer may metastas
diagnosi prostat cancer detect and/or imag physician perform prostat tissu
biopsi pathologist qualit assess cellular characterist biopsi process known
gleason score prognost test determin sever diseas assign score
indic best prognosi worst
addit physician also provid descript diseas via tumor-node-metastasi tnm stage
tnm stage first introduc provid descript primari tumor size
locat metastasi diseas lymph node area outsid pelvi descript
stage describ figur
primari tumor evalu
evid primari tumor
cancer small seen scan felt
cancer present complet insid prostat gland
cancer broken capsul prostat
cancer spread bodi organ
region lymph node evalu
cancer spread region lymph node
cancer spread region lymph node pelvi
unknown cancer spread distant site
diseas metastas
distant metastasi
treatment option treatment option prostat cancer variabl depend sever diseas
rang activ surveil drastic intervent prescrib cours intervent made base
combin factor includ level gleason score famili histori patient local
cheng et al stage prostat cancer histopatholog
grade stage prostat cancer prostat cancer foundat australia http //www prostat org au/awareness/for-
prostat cancer gener three treatment option includ activ surveil prostatectomi
radiat therapi addit experiment treatment option high intens focus ultrasound hifu
also develop prostatectomi radiat therapi treatment associ higher risk undesir
side effect includ erectil dysfunct urinari incontin caus neg impact patient qualiti
life addit inform
activ surveil patient diseas local slow-grow immedi need
treatment activ surveil offer patient hope avoid unnecessari potenti harm
treatment consist monitor prostat cancer measur serum biopsi mri
chang assess signal diseas progress treat immedi
prostatectomi procedur surgeon either complet remov resect section prostat
gland remov prostate-loc cancer cell perform use tradit surgeri use
minim invas option robot-assist laparoscop prostatectomi procedur primarili
recommend younger year age and/or healthier men year life expect
classifi low-risk patient high probabl
radiat therapi local radiat use kill prostat cancer cell use procedur
low-dos rate ldr brachytherapi image-guid intens modul radiat therapi ig-imrt
stereotact bodi radiotherapi sbrt although method effect healthi cell also affect
radiat result possibl side effect radiat therapi recommend patient
local intermediate-risk diseas combin androgen depriv therapi howev
treatment option associ increas risk sever advers treatment-rel event sexual
dysfunct compar activ surveil
cancer deem high risk metastas patient cancer progress follow period
remiss hormon therapi androgen depriv therapi combin radiat therapi often
use prostat cancer use androgen androgen receptor ar signal growth reduc androgen
level bodi patient may abl slow cancer growth treatment success reduc
level androgen effect usual short-liv men ultim progress treatment
addit array signific treatment-rel includ sexual dysfunct chang bodi
composit cognit defect metabol effect figur list fda approv prostat cancer
treatment combin radiat therapi treatment cancer progress follow surgeri
radiat advantag space sinc treatment maintain testosteron level patient
mild side effect profil thu potenti allow chronic administr mainten therapi
figur treatment reduct androgen level
address us market although current test second-lin set could use first-
line set well prove efficaci on-going clinic trial thu present address us market
use first-lin second-lin set
us one nine men diagnos prostat cancer lifetim averag age year
approxim new case prostat cancer diagnos roughli
new case classifi non-metastat local stage repres
number individu diagnos year could elig receiv first-lin treatment
depend age patient aggress diseas physician may recommend activ
surveil prostatectomi radiat therapi first-lin treatment approxim patient diagnos
local prostat cancer opt activ surveil remain patient undergo
prostatectomi radiat therapi first-lin recurr rate follow latter treatment option
approxim patient repres number patient year could elig
second-lin calcul present figur addit note incid
prostat cancer increas age life expect continu increas age global popul
incid diseas like rise
hassanipour-azgomi et al incid mortal prostat cancer relationship human
figur us market opportun local prostat cancer
prostat cancer patient us
prostatectomi
clinic data discuss treatment prostat cancer
phase ib/ii studi prostat cancer
trial design open-label dose escal phase ib/ii studi evalu patient non-
metastat prostat cancer fail declin androgen depriv therapi phase ib portion
studi expect enrol two cohort patient first cohort patient treat daili
combin therapi consist mg tyrosin isom mg phenytoin methoxsalen mg
sirolimu second cohort receiv mg tyrosin isom mg tyrosin isom time per day plu
mg phenytoin methoxsalen mg sirolimu second portion studi includ patient
receiv optimum dose identifi phase ib portion studi primari endpoint trial includ
determin dose-limiting-tox maximum toler dose notabl secondari endpoint
includ safeti toler chang circul tumor cell ctc level radiographi per respons
evalu criteria solid tumor recist criteria period
preliminari result interim result on-going studi present american societi clinic
oncolog genitourinari symposium februari dose limit toxic dlt drug relat
seriou advers event report either phase ib phase ii portion studi patient report
possibl drug relat grade includ vitiligo hot flash bradycardia intestin bloat flatul grade
observ patient patient grade ae figur present preliminari efficaci
result on-going studi patient show improv ctc count show radiograph
progress free surviv rpf patient sought subsequ toxic therapi
figur interim result on-going phase ib/ii studi
summari on-going phase ib/ii trial
biomark recurr prostat cancer
improv circul
need subsequ toxic
blood stream often earli indic metastasi patient prostat cancer compani
report treat patient reduct patient least one measur
report undetect treatment occur median period week note
differ method detect blood yield vari result highlight earli stage technolog
suggest studi use technolog view caution although advis caution
compar clinic trial result across studi data present thu far favor given expect
radiograph recurr month biochem recurr approxim compar median
month follow studi final data trial expect late
competit landscap local prostat cancer
second-lin set follow recurr local prostat cancer would directli compet
hormon androgen depriv therapi treatment option mention previous
array signific treatment-rel includ sexual dysfunct chang bodi composit cognit
defect metabol effect could give distinct advantag continu show favor safeti
efficaci profil clinic trial addit cur patient ultim progress treatment
prove significantli increas overal surviv patient could gain meaning market share
although current explor treatment local prostat cancer first-lin set
drug combin could consid prove safe efficaci on-going phase i/iia studi
treatment biochem recurr local prostat cancer american urolog associ aua
guidelin current recommend activ surveil prostatectomi radiat therapi first-lin treatment
option local prostat cancer potenti use combin therapeut
approach increas clinic benefit addit data support safeti efficaci could becom
prefer treatment option either first- second-lin set
current hold five us patent list figur includ patent protect use
treatment breast pancreat metastat cancer addit compani patent china
japan
pharmaceut composit method
pharmaceut composit method
tyrosin deriv composit
high-spe centrifug mix devic
method use
pharmaceut composit method
 patent trademark organ
co-found chief execut offic chief scienc offic
steve co-found inc chief execut offic year experi
biochemistri physic steve lead author patent last decad focus
biopharmaceut oncolog metabol syndrom central nervou system disord prior work
biotech involv chemistri aerospac laser optic addit lead scientif develop
compani work multipl fortun healthcar compani academ institut
us govern
co-found chief oper offic
michael co-found inc chief oper offic michael year execut
experi focu financ oper market respons overse
corpor product develop activ prior michael led oper mikronit
technolog develop market product use advanc materi scienc mikronit oversaw
success develop market sever product well implement collabor depuy
ge depart defens
mr taylor presid chief offic sinc april join inc
year life scienc experi invest bank emerg growth compani recent head
commerci pharma barclay capit inc prior barclay mr taylor spent ten year goldman sach
co held varieti role includ head emerg pharma co-head chines southeast
asian healthcar within
invest bank divis career primarili focus
biopharmaceut work advisor hundr compani variou stage develop
countri mr taylor extens experi pharmaceut busi model scienc financ
strateg transact addit invest bank also spent two year medic diagnost start-up
lead financ busi develop function mr taylor graduat brown univers honor
dr del prior join inc serv nation director gynecolog oncolog cancer treatment
center america ctca also serv southeastern region director prior ctca dr del prior
professor director gynecolog oncolog indiana univers school medicin indianapoli
direct gynecolog oncolog fellowship program continu teach previous also serv
director gynecolog oncolog new york downtown hospit montefior medic center bellevu
hospit new york citi well assist director gynecolog oncolog new york univers school
medicin giusepp del prior md mph involv drug devic procedur develop
entir career particip advisori board studi major pharmaceut
compani industri kol opinion earn invit present fda regulatori
agenc work report front page ny time wsj nearli everi media outlet
principl investig sever world first includ breakthrough oncolog fertil area
scienc dr del prior remain sought-aft clinician bring relev insight actual patient challeng directli
board room dr del prior earn doctor medicin distinct research state univers
new york downstat medic center brooklyn studi citi univers new york brooklyn
colleg combin bachelor arts/doctor medicin program earn degre seven year dr del
prior graduat magna cum laud bachelor art philosophi valedictorian medic school
class receiv master public health biostatist epidemiolog univers illinoi
chicago complet train northwestern univers univers rochest news
world report name dr del prior one best doctor
activ research prolif writer author publish paper book chapter
abstract written three book dr del prior receiv two patent other pend serv
sever committe organ includ current appoint societi gynecolog oncologist
previous gynecolog oncolog group nation cancer institut cooper group also
examin american osteopath associ board obstetr gynecolog gyn oncolog subspecialti
section free time dr del prior given back commun serv volunt physician part
nation associ free charit clinic volunt firefight westchest counti new york
auxiliari polic offic new york polic depart volunt ambul driver ridg
mr stanicki join inc team januari clinic oper offic focus
overse oper deliveri current upcom clinic trial conduct year
experi clinic oncolog research oper mr stanicki extens experi manag
design execut evalu clinic trial cancer therapi join quintil
work sinc clinic oper manag within oncolog therapeut area specif expertis
within phase trial manag field-bas oper deliveri well project-bas oper
prior role prior mr stanicki work seven year perform manag clinic oncolog research
co two year john wayn cancer institut santa monica california
jonathan eckard ph new chief scientif affair offic inc dr eckard work
biotechnolog sector year financi experi follow biotechnolog sector bring
import industri insight understand healthcar equiti market time
wall street receiv sever accolad includ institut investor best up-and-com rise
recent dr eckard chief busi strategi offic oncolog -focus biotechnolog compani
previou financ role director senior equiti research analyst barclay capit market cover
small- mid-cap biotechnolog sector prior join barclay dr eckard work three year citi
analyst cover biotechnolog specialti pharmaceut sector previous spent five year
leerink swann two year hsbc work biotechnolog equiti research
prior career financi servic dr eckard academia conduct cancer research teach
nyu school medicin earn bs biochemistri ohio univers ms toxicolog phd
toxicolog carcinogenesi nyu school medicin
risk invest
consid invest high-risk invest develop stage compani
histori take treatment market current fda approv drug portfolio sever
compani tri target indic cancer treatment pipelin especi crowd
competitor tyme lead program yet gener pivot data limit clinic data date
furthermor earli indic efficaci necessarili translat posit late-stag result
compani may unabl obtain suffici capit fund plan develop program
regulatori risk associ develop drug may receiv fda approv
candid despit signific time financi invest regulatori approv market sell drug
guarante drug penetr market sale may meet expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
